Selection of appropriate therapy in patients with late-onset multiple sclerosis – case report Case report
Article Sidebar
Published:
Mar 31, 2024
Keywords:
multiple sclerosis, relapsing-remitting form, DMT
Main Article Content
Abstract
Multiple sclerosis is a chronic disease of the nervous system that can lead to disability. The successful development of disease-modifying therapies has significantly improved treatment outcomes and life expectancy for people with multiple sclerosis. Multiple sclerosis is thought to be a disease of young people, as most cases occur between the ages of 20 and 40, however, this condition can affect older people. Then, in such a population, it poses quite a therapeutic challenge due to the safety and efficacy of disease-modifying therapies.
Article Details
Issue
Section
Articles
Copyright © by Medical Education. All rights reserved.
References
1. Vaughn CB, Jakimovski D, Kavak KS et al. Epidemiology and treatment of multiple sclerosis in elderly populations. Nat Rev Neurol. 2019; 15(6): 329-42.
2. Hooge JP, Redekop WK. Multiple sclerosis with very late onset. Neurology. 1992; 42(10): 1907-10.
3. Grebenciucova E, Berger JR. Immunosenescence: the Role of Aging in the Predisposition to Neuro-Infectious Complications Arising from the Treatment of Multiple Sclerosis. Curr Neurol Neurosci Rep. 2017; 17: 61.
4. Shirani A, Zhao Y, Petkau J et al. Multiple sclerosis in older adults: the clinical profile and impact of interferon beta treatment. Biomed Res Int. 2015; 2015: 451912.
5. Salter A, Lancia S, Cutter G et al. Characterizing Long-term Disability Progression and Employment in NARCOMS Registry Participants with Multiple Sclerosis Taking Dimethyl Fumarate. Clin Ther. 2018; 40(12): 2077-87.
6. Frischer JM, Weigand SD, Guo Y et al. Clinical and pathological insights into the dynamic nature of the white matter multiple sclerosis plaque. Ann Neurol. 2015; 78(5): 710-21.
2. Hooge JP, Redekop WK. Multiple sclerosis with very late onset. Neurology. 1992; 42(10): 1907-10.
3. Grebenciucova E, Berger JR. Immunosenescence: the Role of Aging in the Predisposition to Neuro-Infectious Complications Arising from the Treatment of Multiple Sclerosis. Curr Neurol Neurosci Rep. 2017; 17: 61.
4. Shirani A, Zhao Y, Petkau J et al. Multiple sclerosis in older adults: the clinical profile and impact of interferon beta treatment. Biomed Res Int. 2015; 2015: 451912.
5. Salter A, Lancia S, Cutter G et al. Characterizing Long-term Disability Progression and Employment in NARCOMS Registry Participants with Multiple Sclerosis Taking Dimethyl Fumarate. Clin Ther. 2018; 40(12): 2077-87.
6. Frischer JM, Weigand SD, Guo Y et al. Clinical and pathological insights into the dynamic nature of the white matter multiple sclerosis plaque. Ann Neurol. 2015; 78(5): 710-21.